Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac

The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile. Much less is known about the Wuhan-Hu-1 strain-based vaccines in the pediatric populati...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Diego A. Díaz-Dinamarca, Simone Cárdenas-Cáceres, Nicolás A. Muena, Pablo Díaz, Gisselle Barra, Rodrigo Puentes, Daniel F. Escobar, Michal Díaz-Samirin, Natalia T. Santis-Alay, Cecilia Canales, Janepsy Díaz, Heriberto E. García-Escorza, Alba Grifoni, Alessandro Sette, Nicole D. Tischler, Abel E. Vasquez
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-08-01
Colecção:	Vaccines
Assuntos:	SARS-CoV-2 SARS-CoV-2 neutralizing antibodies COVID-19 BNT162b2 (Pfizer-BioNTech) CoronaVac heterologous vaccination
Acesso em linha:	https://www.mdpi.com/2076-393X/12/8/919
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!